Chiesi Farmaceutici S.p.A.: all 299 studies

Page 2 of 3. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn WoundsCompletedNCT01657292Phase 3Results posted
• Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic PatientsCompletedNCT01577082Phase 3Results posted
• Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) InhibitorCompletedNCT01556906Phase 2Results posted
• Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01483924Phase 2Results posted
• Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3Results posted
• Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)CompletedNCT01294241Phase 2Results posted
• A Study in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01245569Phase 3Results posted
• Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT00943306Phase 3Results posted
• A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®CompletedNCT00885365Phase 3Results posted
• Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)CompletedNCT00861926Phase 3Results posted
• The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic KeratosesCompletedNCT00786994Phase 2Results posted
• A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)CompletedNCT00730236Phase 3Results posted
• Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in HypercholesterolemiaCompletedNCT00690443Phase 2Results posted
• Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRSCompletedNCT00559962Phase 2Results posted
• Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric PatientsCompletedNCT00529152Phase 3Results posted
• AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate HypercholesterolemiaCompletedNCT00474240Phase 2Results posted
• The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate HypercholesterolemiaCompletedNCT00405067Phase 2Results posted
• Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering AgentsCompletedNCT00359281Phase 2Results posted
• A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE AttacksCompletedNCT07009262
• A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001CompletedNCT06900816Phase 2
• Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) StudyCompletedNCT06892756Phase 1
• Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life SettingCompletedNCT06786767
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 ExposureCompletedNCT06746064Phase 1
• Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With SebetralstatApproved for marketingNCT06628713
• Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyTerminatedNCT06502990Phase 3
• Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)CompletedNCT06480890
• Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy VolunteersCompletedNCT06395610Phase 1
• Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).CompletedNCT06264674Phase 3
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With BronchiectasisCompletedNCT06166056Phase 1/2
• Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world SettingCompletedNCT06100042
• Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance TherapyTerminatedNCT06029595Phase 2
• Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®CompletedNCT05898984Phase 1
• A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)CompletedNCT05830071Phase 1
• NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD PatientsCompletedNCT05743608
• PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialCompletedNCT05511922Phase 3
• An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedNCT05505916Phase 3
• PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy VolunteersCompletedNCT05431426Phase 1
• Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control SubjectsCompletedNCT05373953Phase 1
• Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly InfusionCompletedNCT05186324
• A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy VolunteersCompletedNCT05178355Phase 1
• Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma ControlCompletedNCT05168995
• Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLActive, not recruitingNCT05164341Phase 3
• Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) FormulationsCompletedNCT05118958Phase 1
• CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPDCompletedNCT05097014Phase 4
• Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABATerminatedNCT05018598Phase 4
• Global Burden and Treatment Trajectiories in Italian Patients With Fabry DiseaseCompletedNCT04916977
• A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comesCompletedNCT04902573
• Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)CompletedNCT04739774Phase 1
• TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPDWithdrawnNCT04671355Phase 4
• A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)TerminatedNCT04636814Phase 3
• A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)TerminatedNCT04636801Phase 3
• Study on Patterns of Care in Mild Asthmatic PatientsCompletedNCT04598555
• Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease PatientsApproved for marketingNCT04552691
• ARCANGELO (itAlian pRospective Study on CANGrELOr)CompletedNCT04471870
• Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple TherapyCompletedNCT04355546
• A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCompletedNCT04349800Phase 1
• A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDCompletedNCT04320342Phase 3
• CHF6467 SAD and MAD in Patients With Diabetic Foot UlcerCompletedNCT04077671Phase 1/2
• Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes RegistryActive, not recruitingNCT04076813
• Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic AsthmaTerminatedNCT04049175Phase 3
• Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD SubjectsCompletedNCT04032535Phase 1
• Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha MannosidosisWithdrawnNCT04031066Phase 3
• A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) BronchiectasisCompletedNCT04010799Phase 1
• Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) FunctionalityWithdrawnNCT03992443Phase 3
• Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)CompletedNCT03963167
• Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's AdherenceCompletedNCT03951714Not applicable
• PK Linearity and Steady State PK of CHF 6532 in Healthy SubjectsCompletedNCT03942666Phase 1
• PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. CaucasiansCompletedNCT03859414Phase 1
• The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDSCompletedNCT03808402
• Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD PatientsTerminatedNCT03795350Phase 1
• Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease PatientsCompletedNCT03614234Phase 3
• Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03590379Phase 2
• The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant RecipientsCompletedNCT03558373
• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366CompletedNCT03378648Phase 1/2
• Functional Respiratory Imaging Study (FRI)CompletedNCT03268226Phase 3
• A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)TerminatedNCT03235986Phase 2
• A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.CompletedNCT03108534Phase 2
• A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy SubjectsCompletedNCT03056326Phase 1
• Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001CompletedNCT03004495Phase 1
• Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPDCompletedNCT03004417Phase 2
• Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-MannosidosisCompletedNCT02998879Phase 2
• A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPDCompletedNCT02986321Phase 2
• Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD PatientsCompletedNCT02975843Phase 1
• Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical StudyCompletedNCT02970630Phase 2
• A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPDTerminatedNCT02815488Phase 1/2
• Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years OldCompletedNCT02787967Phase 2
• Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering TherapyWithdrawnNCT02765841Phase 3
• Cangrelor Neonatal PK/PD and Safety StudyCompletedNCT02765633Phase 1
• Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy VolunteersCompletedNCT02743013Phase 1
• Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPDCompletedNCT02680197Phase 2
• Compassionate Use of Deferiprone in Patients With PKANNo longer availableNCT02635841
• 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD PatientsCompletedNCT02579850Phase 3
• Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaCompletedNCT02560610Phase 2
• Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant PatientsCompletedNCT02500212Phase 4
• Evaluation of Long-term Efficacy of Treatment With LamazymCompletedNCT02478840Phase 3
• Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02467452Phase 3
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive SubjectsCompletedNCT02456558Phase 1
• Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant PatientsCompletedNCT02432833Phase 4
• Effects of Lomitapide on Carotid and Aortic AtherosclerosisWithdrawnNCT02399852
• Global Lomitapide Pregnancy Exposure RegistryTerminatedNCT02399839

← Chiesi Farmaceutici S.p.A. overview and focus areas